Why Viking Therapeutics Stock Skyrocketed on Tuesday

Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates, positioning Viking as a potential challenger in the rapidly expanding obesity drug market projected to reach $150 billion by 2035.